CO-AEM
24.1.2022 14:07:04 CET | Business Wire | Press release
AEM today announced the highly anticipated update of the Earth Networks Total Lightning Network® (ENTLN). With significant enhancements to both location accuracy and lightning detection efficiency, the ENTLN now improves the ability for AEM customers to track real-time lightning and provide early warning for severe weather events that could threaten public safety and operational effectiveness.
The enhancements are driven through redesigns of the proprietary ENTLN algorithms and include:
- Exceptional lightning location accuracy now under 100 meters. With enhanced accuracy, those in charge of keeping people and assets safe from severe weather have further precision to make confident decisions in moments that matter.
- Detection efficiency over 95% regionally, with 30-50% more lightning detected worldwide. With increased detection efficiency, the ENTLN improves upon its industry leading reliability.
- 90% cloud-to-ground and in-cloud lightning classification accuracy . For customers who make decisions based on the type of lightning, improved classification enhances the ability to track lightning events relevant to a specific situation.
Lightning data from ENTLN is now available in expanded data formats for seamless consumption into 3rd party applications to investigate weather events, verify strikes and analyze lightning induced damage. These new network capabilities are also accompanied by a redesigned lightning sensor allowing for easier deployments and maintenance in remote environments.
The new lightning offering is now integrated into AEM’s suite of decision support applications including:
- Earth Networks Sferic Products – for safeguarding lives and assets from severe weather including lightning, high winds, and heavy precipitation, the Sferic product line provides over 120 map layers displaying current conditions and forecasting and enables custom alerts to be delivered via email, text, or via push notifications to a companion mobile app.
- OneRain Contrail® – for flood risk management and warning, dam safety, and reservoir gate operations, Contrail delivers lightning information to ensure first responder safety and identify more vigorous convective storms that may exacerbate local flash flooding and high-water conditions.
- FTS360 – for wildfire monitoring and mitigation, FTS360 integrates sensor and station data, camera imagery, and video to provide complete situational awareness of current and potential wildfire events. The lightning data improves response time by providing early detection and verification of potential wildfire ignitions.
“With environmental risks escalating and increased impacts from severe weather events around the world, both the public and private sectors are growing increasingly dependent on real-time weather insights to drive their emergency action plans, keep people safe, and minimize downtime,” said Mark Miller, Chief Commercial Officer, AEM. “We are excited to bring these improvements to our industry-leading lightning detection network and ensure decision makers have access to the most trusted and reliable lightning data on the market.”
“As an early adopter of the new ENTLN, we have been impressed with the increased detection efficiency and location accuracy it has brought to the Australia Total Lightning Network (ATLN),” said Martin Palmer, Managing Director, WeatherZone. “Their data, along with our solutions and insights, provides our customers with the operational intelligence they need to make agile and confident decisions. Earth Networks enables us to provide a comprehensive solution to organisations and businesses across Australia.”
Operating over 1,800 sensors across 100 countries, the Earth Networks Total Lightning Network is the most advanced global lightning network in the world. Its ability to comprehensively monitor both in-cloud and cloud-to-ground lightning enables the creation of faster severe weather alerts, lightning-derived radar alternatives and real-time storm visualization.
The new lightning network capabilities, as well as AEM’s broader set of environmental risk solutions, are on display at the American Meteorological Society (AMS) 102nd Annual Meeting from now until January 27, 2022. To learn more visit AEM at https://aem.eco .
About AEM
AEM is combining global technology leaders to empower communities and organizations to survive and thrive in the face of escalating environment risks. By deploying intelligent sensing networks, operating a secure and scalable data management infrastructure, and delivering high-value analytics through a suite of end-user applications, AEM serves as the essential source for environmental insights. These technologies enable positive outcomes, helping reduce environmental impact and creating a safer world. For more information, visit https://aem.eco .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005052/en/
Link:
Social Media:
https://www.facebook.com/Advanced-Environmental-Monitoring-AEM-110375228108391
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
